Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.

Animals Cell Line, Tumor Cisplatin / therapeutic use Enhancer of Zeste Homolog 2 Protein / physiology Female Histocompatibility Antigens Histone-Lysine N-Methyltransferase / antagonists & inhibitors Humans Mice Programmed Cell Death 1 Receptor / antagonists & inhibitors Urinary Bladder Neoplasms / drug therapy

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
07 2019

Historique:

received: 15 06 2018

accepted: 24 05 2019

pubmed: 5 7 2019

medline: 15 11 2019

entrez: 5 7 2019

Statut: ppublish

Résumé

Bladder cancer is lethal in its advanced, muscle-invasive phase with very limited therapeutic advances

Identifiants

DOI: 10.1038/s41591-019-0499-y PMID: 31270502

pubmed: 31270502

doi: 10.1038/s41591-019-0499-y

pii: 10.1038/s41591-019-0499-y

doi:

Substances chimiques

Histocompatibility Antigens 0

Programmed Cell Death 1 Receptor 0

EHMT2 protein, human EC 2.1.1.43

EZH2 protein, human EC 2.1.1.43

Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43

Histone-Lysine N-Methyltransferase EC 2.1.1.43

Cisplatin Q20Q21Q62J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1073-1081

Commentaires et corrections

Type : CommentIn

Références

Zibelman, M. & Plimack, E. R. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 12, 2227–2242 (2016).

pubmed: 27402371 pmcid: 5066115

Sanli, O. et al. Bladder cancer. Nat. Rev. Dis. Primers 3, 17022 (2017).

pubmed: 28406148

Weinstein, J. N. et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).

Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540–556.e525 (2017).

pubmed: 28988769 pmcid: 5687509

Plimack, E. R. et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 18, 212–220 (2017).

pubmed: 28081914

Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).

pubmed: 28212060 pmcid: 5635424

Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017).

pubmed: 27939400

Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).

pubmed: 26952546 pmcid: 5480242

Stenzl, A. et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol. 59, 1009–1018 (2011).

pubmed: 21454009

Casciello, F., Windloch, K., Gannon, F. & Lee, J. S. Functional role of G9a histone methyltransferase in cancer. Front. Immunol. 6, 487 (2015).

pubmed: 26441991 pmcid: 4585248

Li, F. et al. G9a inhibition induces autophagic cell death via AMPK/mTOR pathway in bladder transitional cell carcinoma. PLoS ONE 10, e0138390 (2015).

pubmed: 26397365 pmcid: 4580411

Dueñas, M. et al. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol. Carcinog. 54, 566–576 (2015).

pubmed: 24347284

Santos, M. et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 74, 6565–6577 (2014).

pubmed: 25252918 pmcid: 4233185

San José-Enériz, E. et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat. Commun. 8, 15424 (2017).

pubmed: 28548080 pmcid: 5458547

Sweis, R. F. et al. Discovery and development of potent and selective inhibitors of histone methyltransferase G9a. ACS Med. Chem. Lett. 5, 205–209 (2014).

pubmed: 24900801 pmcid: 4027767

Earl, J. et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics 16, 403 (2015).

pubmed: 25997541 pmcid: 4470036

Segovia, C. et al. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget 8, 10531–10542 (2017).

pubmed: 28060766 pmcid: 5354678

Bárcena-Varela, M. et al. Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma. Hepatology 69, 587–603 (2019).

pubmed: 30014490

Coward, W. R. et al. Interplay between EZH2 and G9a regulates CXCL10 gene repression in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 58, 449–460 (2018).

pubmed: 29053336 pmcid: 5894498

Mozzetta, C. et al. The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing. Mol. Cell 53, 277–289 (2014).

pubmed: 24389103

McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012).

pubmed: 23051747

Witjes, J. A. et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol. 65, 778–792 (2014).

pubmed: 24373477

Puzio-Kuter, A. M. et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23, 675–680 (2009).

pubmed: 19261747 pmcid: 2661614

Rubio, C. et al. CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status. Clin. Cancer Res. 25, 390–402 (2019).

pubmed: 30242024

Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015).

pubmed: 26317466 pmcid: 26317466

Wang, Y. et al. Negative feedback regulation of IFN-γ pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res. 68, 1136–1143 (2008).

pubmed: 18281489

Stone, M. L. et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl Acad. Sci. USA 114, E10981–E10990 (2017).

pubmed: 29203668

Cribbs, A. et al. Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J. Biol. Chem. 293, 2422–2437 (2018).

pubmed: 29301935 pmcid: 5818173

Topper, M. J. et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171, 1284–1300.e21 (2017).

pubmed: 5808406 pmcid: 5808406

Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).

Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).

pubmed: 28102259

Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).

pubmed: 28967485

Li, X. et al. Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages. J. Autoimmun. 80, 85–94 (2017).

pubmed: 28284523

Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770–775 (2018).

pubmed: 29301958 pmcid: 29301958

Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).

pubmed: 29301960 pmcid: 29301960

Costa, C. et al. A novel tumor suppressor network in squamous malignancies. Sci. Rep. 2, 828 (2012).

pubmed: 23145321 pmcid: 3494016

Moral, M. et al. Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. Cancer Res. 69, 1099–1108 (2009).

pubmed: 19176372 pmcid: 2914485

Ramírez, A., Bravo, A., Jorcano, J. L. & Vidal, M. Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation 58, 53–64 (1994).

pubmed: 7532601

Martínez-Fernández, M. et al. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. Oncotarget 6, 42258–42275 (2015).

pubmed: 26517683 pmcid: 4747223

Chou, T. C. & Talalay, P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22, 27–55 (1984).

Roman-Gomez, J. et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J. Clin. Oncol. 27, 1316–1322 (2009).

pubmed: 19164206

Saeed, A. I. et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34, 374–378 (2003).

pubmed: 12613259

Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

pubmed: 16199517

Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).

pubmed: 23586463 pmcid: 3637064